OMX

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

Retrieved on: 
Tuesday, April 2, 2024
Health, Advisory Committee, Disease, OMX, Partnership, Risk, Trust, Pharmacy, Public, Mpox, Infection, CDC, Vaccination, Vaccine, FDA, Government, ACIP, Pharmaceutical industry

Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at risk of mpox infection.

Key Points: 
  • Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at risk of mpox infection.
  • According to estimates from the CDC, two (2) million U.S. individuals are eligible for vaccination against mpox4.
  • Recent data shows 60% of this population remains completely unvaccinated, and 15% have received only one dose of the vaccine5.
  • Through its existing nationwide vaccine distribution structure, Bavarian Nordic is now making the mpox vaccine commercially available across the nation.

Amendment - 2023 Full Year Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Financial statement, Environmental impact assessment, Icelandic, Vein, Government, Mining, Growth, Fundraising, Bed, OMX, FY, Nanoq, ESG, Webcast, Corporation, Gold, Copper, Q4, Rehabilitation, Social impact assessment, SIA, Capital market, REE, Niobium, IOCG, Workforce, Unit, EIA, AIM, Nasdaq Iceland, Engineering, Person, Rare-earth element

Amendments have been made to the ‘2023 Full Year Financial Results’ announcement released on 26 March 2024 at 07:00 in the Financial Results table.

Key Points: 
  • Amendments have been made to the ‘2023 Full Year Financial Results’ announcement released on 26 March 2024 at 07:00 in the Financial Results table.
  • “We experienced some operational and procurement delays towards the end of 2023 due to adverse weather conditions, which continued into the start of 2024.
  • Amaroq will continue to review the results of the detailed geophysical programme conducted over the Kobberminebugt licence in 2023.
  • The following selected financial data is extracted from the Financial Statements for the three months ended December 31, 2023.

2023 Full Year Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Financial statement, Environmental impact assessment, Icelandic, Vein, Government, Mining, Growth, Fundraising, Bed, OMX, FY, Nanoq, ESG, Webcast, Corporation, Gold, Copper, Q4, Rehabilitation, Social impact assessment, SIA, Capital market, REE, Niobium, IOCG, Workforce, Unit, EIA, AIM, Nasdaq Iceland, Engineering, Person, Rare-earth element

“We experienced some operational and procurement delays towards the end of 2023 due to adverse weather conditions, which continued into the start of 2024.

Key Points: 
  • “We experienced some operational and procurement delays towards the end of 2023 due to adverse weather conditions, which continued into the start of 2024.
  • Contracting and Procurement: At the end of Q4 2023, 80% of the key contracts for the processing plant were concluded and procurement was 80% completed.
  • Amaroq will continue to review the results of the detailed geophysical programme conducted over the Kobberminebugt licence in 2023.
  • The following selected financial data is extracted from the Financial Statements for the three months ended December 31, 2023.

Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency

Retrieved on: 
Friday, February 23, 2024
Marketing, EMA, Marketing Authorisation Application, Committee, MAA, Food, BLA, Nature, Vaccination, CHMP, European Medicines Agency, Public, Chikungunya, OMX, Ageing, CHIKV, Vaccine

Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024.

Key Points: 
  • Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024.
  • COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment for the upcoming Marketing Authorisation Application (MAA) for CHIKV VLP, the Company’s investigational chikungunya vaccine.
  • Bavarian Nordic is on track and plans to submit its MAA for CHIKV VLP to the EMA during H1 2024.
  • “We are pleased to receive the accelerated assessment in recognition of our chikungunya vaccine candidate and our efforts to bring this novel product to the market.

Annual General Meeting in ALK-Abelló A/S on 14 March 2024

Retrieved on: 
Friday, February 16, 2024
A/S, Annual, OMX, AGM

ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark.

Key Points: 
  • ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark.
  • The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.
  • For further information please contact:

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

Retrieved on: 
Wednesday, February 7, 2024
Telephone, Sale, OTC, Tablet, Pharmacy, OMX, Risk, Pharmaceutical industry

The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.

Key Points: 
  • The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.
    "
  • Allderma's approach and good results demonstrate why they are an excellent partner in our home market."
  • The goal is the same as last time, to achieve a market-leading position", says Mimmi Frölén, CEO of Allderma AB.
  • Anna Ljung, CEO, telephone: +46 707 66 60 30, E-mail: [email protected]
    Anders Bröijersén, Chief Medical Officer, telephone: +46 760 01 15 76, E-mail: [email protected]

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

Retrieved on: 
Wednesday, February 7, 2024
Telephone, Sale, OTC, Tablet, Pharmacy, OMX, Risk, Pharmaceutical industry

The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.

Key Points: 
  • The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.
    "
  • Allderma's approach and good results demonstrate why they are an excellent partner in our home market."
  • The goal is the same as last time, to achieve a market-leading position", says Mimmi Frölén, CEO of Allderma AB.
  • Anna Ljung, CEO, telephone: +46 707 66 60 30, E-mail: [email protected]
    Anders Bröijersén, Chief Medical Officer, telephone: +46 760 01 15 76, E-mail: [email protected]

Admission to OMX Iceland 15 Index

Retrieved on: 
Wednesday, December 27, 2023
OMX, Index, Nasdaq Iceland, Gold, AIM

TORONTO, ONTARIO – December 27, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development corporation with a substantial land package of gold and strategic mineral assets across in Southern Greenland, is pleased to announce that the Company’s shares will be admitted to the OMX Iceland 15™ Index prior to market open on Tuesday, January 2, 2024.

Key Points: 
  • TORONTO, ONTARIO – December 27, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development corporation with a substantial land package of gold and strategic mineral assets across in Southern Greenland, is pleased to announce that the Company’s shares will be admitted to the OMX Iceland 15™ Index prior to market open on Tuesday, January 2, 2024.
  • The OMX Iceland 15™ Index measures the performance of a selection of the most traded and largest securities listed on Nasdaq Iceland.
  • The index is made up of a maximum of 15 constituents.
  • A link to the Nasdaq announcement is set out below:

VedaBio Launches with Over $40 Million to Revolutionize Molecular Detection

Retrieved on: 
Tuesday, October 17, 2023
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Entrepreneurship, Gold, Therapy, OMX, Engineering, CRISPR, Doctor of Philosophy, Biology, Fine chemical, Medical imaging

VedaBio , the biotechnology company leading a paradigm-shift in molecular detection, today launched with initial funding of over $40 million backed by lead investor OMX Ventures along with a select group of family offices, including Kleinmuntz Associates.

Key Points: 
  • VedaBio , the biotechnology company leading a paradigm-shift in molecular detection, today launched with initial funding of over $40 million backed by lead investor OMX Ventures along with a select group of family offices, including Kleinmuntz Associates.
  • VedaBio has unlocked the true power of CRISPR for molecular detection by developing the CRISPR Cascade, a revolutionary platform born from the intersection of engineering and biology.
  • “With the CRISPR Cascade reaction, we have unlocked the true power of CRISPR with a platform that delivers near-instant molecular detection of highly multiplexed analytes with best-in-class accuracy, all without the need for target amplification.
  • We believe it is poised to emerge as a future gold standard for molecular detection, empowering major advances across multiple applications including research and industrial tools, diagnostics and therapeutics,” said Anurup Ganguli, PhD, Co-Founder and Chief Executive Officer of VedaBio.

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Retrieved on: 
Friday, October 6, 2023
Probability, OMX, Onychomycosis, Telephone, Marketing, Patient, Pharmaceutical industry, Airline

STOCKHOLM, Oct. 6, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America.

Key Points: 
  • STOCKHOLM, Oct. 6, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America.
  • The enrollment to the North American study has now been completed with 384 patients randomized at 33 sites in the U.S. and Canada.
  • Moberg Pharma cooperate with the same CRO, lead investigator and successful sites from the previous North American study.
  • "Completing the enrollment in North America well ahead of year-end is an important milestone and the result of excellent teamwork and committed investigators.